Amphotericin Tops Itraconazole in HIV-Linked Talaromycosis

This article originally appeared here.
Share this content:
Amphotericin Tops Itraconazole in HIV-Linked Talaromycosis
Amphotericin Tops Itraconazole in HIV-Linked Talaromycosis

WEDNESDAY, June 14, 2017 (HealthDay News) -- For patients with HIV with talaromycosis, amphotericin B deoxycholate (amphotericin) is superior to itraconazole, according to a study published in the June 15 issue of the New England Journal of Medicine.

Thuy Le, M.D., D.Phil., from Oxford University in the United Kingdom, and colleagues conducted an open-label, noninferiority trial involving 440 HIV-infected adults with talaromycosis. Participants were randomized to receive either intravenous amphotericin (219 patients) or itraconazole capsules (221 patients) for 14 days; thereafter all patients received itraconazole maintenance therapy.

The researchers found that the risk of death at week two was 6.5 and 7.4 percent in the amphotericin and itraconazole groups, respectively (absolute risk difference, 0.9 percentage points; 95 percent confidence interval, −3.9 to 5.6; P < 0.001 for noninferiority). At 24 weeks, the risk of death was 11.3 and 21.0 percent in the amphotericin and itraconazole groups, respectively (absolute risk difference, 9.7 percentage points; 95 percent confidence interval, 2.8 to 16.6; P = 0.006). Compared with itraconazole, amphotericin treatment correlated with significantly faster clinical resolution and fungal clearance and with significantly lower rates of relapse and immune reconstitution inflammatory syndrome. Compared with itraconazole, amphotericin was also associated with significantly higher rates of infusion-related reactions, renal failure, hypokalemia, hypomagnesemia, and anemia.

"Amphotericin was superior to itraconazole as initial treatment for talaromycosis with respect to six-month mortality, clinical response, and fungicidal activity," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Zika Does Not Appear to Last in Semen As Long As Thought

Zika Does Not Appear to Last in Semen ...

More research is needed to better inform public health recommendations

Radioiodine Therapy for Thyroid Cancer Doesn't Up Stroke Risk

Radioiodine Therapy for Thyroid Cancer Doesn't Up Stroke ...

I-131 therapy group showed no significantly higher risk of ischemic or hemorrhagic stroke

Higher Odds of Infection With Reduced Kidney Function

Higher Odds of Infection With Reduced Kidney Function

Study finds excess community-acquired infections incidence in individuals with mild to severe CKD

is free, fast, and customized just for you!

Already a member?

Sign In Now »